FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2556739215> ?p ?o ?g. }

• W2556739215 abstract "Abstract 5284 Introduction: Poor adherence to iron chelation therapy (ICT) in beta-Thalassemia Major (TM) is associated with increased risk of cardiac complications and endocrinopathies, and lower survival, with substantial cost to the patient and the health care system. Canada is unique in that several predictors of non-adherence (Financial barriers to medical care, cost of medication and inadequate follow-up) are minimized due to the presence of universal health care, governmental subsidies for medications for patients with chronic disease, and the availability of comprehensive care center for most of the thalassemia patients in the country. Also, the availability of Deferiprone (DFP) via compassionate release program since July 2004 provides an alternative to patients intolerant or having suboptimal response to Deferoxamine (DFO) or Deferasirox (DFX). We hypothesize that the absence of these barriers improve adherence in the Canadian thalassemic population. We also explored self-efficacy as a concept of adherence behavior in our patient population, defined as “individuals' personal beliefs regarding their capabilities to carry out a specific task to achieve a desired outcome” (Bandura, 1989). Methods: A cross-sectional survey was conducted in June and July 2011 at a regional comprehensive care center for transfusion-dependent thalassemia patients. We assessed the age, sex, education, employment status, insurance coverage, types and dosage of ICT, self-reported level of adherence, and side effects. We adapted the Medication Adherence Self-Efficacy Scale (MASES) to assess self-efficacy (Ogedegbe, 2003). Results: Survey return rate was 45% (46/103), with each type of ICT proportionally represented (P = 0.6401). Eight surveys were discarded due to incompletion and 38 were analyzed. Thirty-two patients were on single agent ICT (6 on DFO, 23 on DFX, 3 on DFP) and 6 patients were on combination treatment (1 on DFO+DFX; 3 on DFO+DFP; 2 on DFX+DFP). Median duration of iron chelation was more than 10 years. All patients had either government (n = 10) or workplace (n = 28) coverage. Twenty-three patients (61%) were self-described as completely adherent and 15 were not completely adherent. Mean level of adherence is 90% (SD 16%), similar to those reported in the literature (Trachtenberg et al., 2011), with no significant difference between the different types of ICT (P = 0.1085). Half of the non-adherent patients (8/15, 53%) miss 1 prescribed day of medication per week. There was no significant difference between adherent and non-adherent patients in age (P = 0.1484), sex (P = 0.3764), type of insurance coverage (P = 4752), family support (P = 0.7190), type of ICT (P = 0.0611), participation and satisfaction with the Exjade Patient Support Program (P = 1.000 and 0.3012 respectively), duration of chelation (P = 0.3951), rate of side effects (P = 0.4167), or feelings of depression (P = 0.4780). There was a trend towards differences in education level (P = 0.0565) and a higher proportion of professionals in the non-adherent group. The mean self-efficacy score of patients self-described as completely adherent was significantly higher than the non-completely adherent group (2.66 vs 1.93, P<0.0001). Discussion: In this self-reported survey of patients on ICT in a Canadian regional comprehensive care center, age, presence of family support, and feelings of depression were not found to be a significant predictor of poor adherence, unlike previous studies. This could be because previous studies only examined certain types of ICTs whereas the present study examined all forms of chelation. Small sample sizes of patients on DFO and DFP is the main limitation of the study. This is also the first known application of self-efficacy theory in explaining adherence to ICT. Further studies are required to examine the internal consistency and test-retest reliability of MASES in evaluating self-efficacy in adherence to ICT. Disclosures: Kuo: Novartis Canada: Research Funding. Off Label Use: Deferiprone is an unlicensed drug in Canada and USA. It is an oral iron chelator." @default.
• W2556739215 created "2016-11-30" @default.
• W2556739215 creator A5064622256 @default.
• W2556739215 creator A5084047203 @default.
• W2556739215 date "2011-11-18" @default.
• W2556739215 modified "2023-09-27" @default.
• W2556739215 title "Application of Self-Efficacy Theory in Adherence to Iron Chelation Therapy: A Single-Center Cross-Sectional Study" @default.
• W2556739215 doi "https://doi.org/10.1182/blood.v118.21.5284.5284" @default.
• W2556739215 hasPublicationYear "2011" @default.
• W2556739215 type Work @default.
• W2556739215 sameAs 2556739215 @default.
• W2556739215 citedByCount "1" @default.
• W2556739215 countsByYear W25567392152016 @default.
• W2556739215 crossrefType "journal-article" @default.
• W2556739215 hasAuthorship W2556739215A5064622256 @default.
• W2556739215 hasAuthorship W2556739215A5084047203 @default.
• W2556739215 hasConcept C126322002 @default.
• W2556739215 hasConcept C142052008 @default.
• W2556739215 hasConcept C142724271 @default.
• W2556739215 hasConcept C187212893 @default.
• W2556739215 hasConcept C2776517179 @default.
• W2556739215 hasConcept C2776672577 @default.
• W2556739215 hasConcept C2777799968 @default.
• W2556739215 hasConcept C2781053155 @default.
• W2556739215 hasConcept C2908647359 @default.
• W2556739215 hasConcept C512399662 @default.
• W2556739215 hasConcept C71924100 @default.
• W2556739215 hasConcept C99454951 @default.
• W2556739215 hasConceptScore W2556739215C126322002 @default.
• W2556739215 hasConceptScore W2556739215C142052008 @default.
• W2556739215 hasConceptScore W2556739215C142724271 @default.
• W2556739215 hasConceptScore W2556739215C187212893 @default.
• W2556739215 hasConceptScore W2556739215C2776517179 @default.
• W2556739215 hasConceptScore W2556739215C2776672577 @default.
• W2556739215 hasConceptScore W2556739215C2777799968 @default.
• W2556739215 hasConceptScore W2556739215C2781053155 @default.
• W2556739215 hasConceptScore W2556739215C2908647359 @default.
• W2556739215 hasConceptScore W2556739215C512399662 @default.
• W2556739215 hasConceptScore W2556739215C71924100 @default.
• W2556739215 hasConceptScore W2556739215C99454951 @default.
• W2556739215 hasLocation W25567392151 @default.
• W2556739215 hasOpenAccess W2556739215 @default.
• W2556739215 hasPrimaryLocation W25567392151 @default.
• W2556739215 hasRelatedWork W1509759498 @default.
• W2556739215 hasRelatedWork W1812079080 @default.
• W2556739215 hasRelatedWork W1994087217 @default.
• W2556739215 hasRelatedWork W2037030720 @default.
• W2556739215 hasRelatedWork W2132492709 @default.
• W2556739215 hasRelatedWork W2282380471 @default.
• W2556739215 hasRelatedWork W2325057488 @default.
• W2556739215 hasRelatedWork W2617987023 @default.
• W2556739215 hasRelatedWork W2755079336 @default.
• W2556739215 hasRelatedWork W2770596085 @default.
• W2556739215 hasRelatedWork W2773165621 @default.
• W2556739215 hasRelatedWork W2802509524 @default.
• W2556739215 hasRelatedWork W2922122667 @default.
• W2556739215 hasRelatedWork W2945691800 @default.
• W2556739215 hasRelatedWork W2995675855 @default.
• W2556739215 hasRelatedWork W3037144074 @default.
• W2556739215 hasRelatedWork W3045817133 @default.
• W2556739215 hasRelatedWork W3085418273 @default.
• W2556739215 hasRelatedWork W3135950235 @default.
• W2556739215 hasRelatedWork W2183635541 @default.
• W2556739215 isParatext "false" @default.
• W2556739215 isRetracted "false" @default.
• W2556739215 magId "2556739215" @default.
• W2556739215 workType "article" @default.